As directors push for technology transformation, a new survey reveals a striking confidence gap in risk oversight—especially ...

The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

When the mail-in ancestry company 23andMe filed for bankruptcy, Regeneron Pharmaceuticals stepped in to snap it up. Though in the end the Tarrytown-based company was outbid, the scenario raised a ...

The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 million upfront in January 2024. Regeneron is pulling the plug on an early ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a consumer advisory reminding former customers of ways to protect their ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks ...

23andMe’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an objection from the Justice Department’s bankruptcy watchdog over ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most undervalued stocks. It is a leading American biotech company specializing in treatments for serious diseases across ophthalmology, ...

What if we could prevent people from developing obesity? The World Obesity Federation expects more than half the global population to develop overweight or obesity by 2035. However, treatment ...

The court-appointed Consumer Privacy Ombudsman (CPO) in the 23andMe bankruptcy last month released a 200-plus-page report assessing the privacy implications of the ...

The sale of 23andMe was finalized this week, following the company filing for bankruptcy in March. The sale was previously approved by a judge. The company was purchased by the nonprofit TTAM Research ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another ...